<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784614</url>
  </required_header>
  <id_info>
    <org_study_id>12662</org_study_id>
    <secondary_id>I2K-JE-ZZAW</secondary_id>
    <nct_id>NCT01784614</nct_id>
  </id_info>
  <brief_title>A Study of LY2624803 in Japanese Participants With Transient Insomnia</brief_title>
  <official_title>Pharmacodynamics and Pharmacokinetics of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy
      Japanese participants. The study has four treatment periods. Participants will receive a
      single dose of LY2624803 or placebo in each treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo</measure>
    <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
    <description>WASO was calculated as total time in awake epochs between sleep onset time (first stage 2 epoch) and the end of the primary recording period (8 hours after lights -off). Data presented are Geometric Least Squares (LS) means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency to Persistent Sleep (LPS)</measure>
    <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
    <description>LPS is defined as the latency from the lights-off time to the first stage 2 sleep followed by at least 10 consecutive minutes of sleep epochs. Data presented are Geometric LS means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time (TST)</measure>
    <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
    <description>TST is defined as the total time in sleep epochs from sleep onset time to the end of the primary recording period (8 hours after lights -off). LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Plasma Concentration (Cmax) of LY2624803 After Single Oral Dose in Period 4</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2624803 After Single Oral Dose in Period 4</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>0.1 milligrams (mg) LY2624803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg LY2624803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg LY2624803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.0 mg LY2624803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally in up to 1 of 4 treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2624803 - Solution</intervention_name>
    <description>Administered orally as reconstituted solution</description>
    <arm_group_label>0.1 milligrams (mg) LY2624803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2624803 - Capsule</intervention_name>
    <description>Administered orally as a capsule</description>
    <arm_group_label>1.0 mg LY2624803</arm_group_label>
    <arm_group_label>3.0 mg LY2624803</arm_group_label>
    <arm_group_label>6.0 mg LY2624803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Solution</intervention_name>
    <description>Administered orally as solution</description>
    <arm_group_label>1.0 mg LY2624803</arm_group_label>
    <arm_group_label>3.0 mg LY2624803</arm_group_label>
    <arm_group_label>6.0 mg LY2624803</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Capsule</intervention_name>
    <description>Administered orally as a capsule</description>
    <arm_group_label>0.1 milligrams (mg) LY2624803</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or female Japanese

          -  Women of child-bearing potential, who test negative for pregnancy at the time of
             enrollment based on a urine pregnancy test and agree to use a reliable method of birth
             control during the study and for 3 months following the last dose of study drug

          -  Body mass index (BMI) of 17.6 to 26.4 kilogram per meter square (kg/m^2), inclusive

          -  Normal bedtime hours, with routine time spent in bed between 6.5 hours and 9 hours
             each night

          -  Clinical laboratory test results within normal reference range

          -  Venous access sufficient to allow blood sampling as per the protocol

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing and able to follow study procedures

          -  Have given written informed consent approved by Lilly and the ethical review board
             governing the site

        Exclusion Criteria:

          -  Within 4 months of the initial dose of study drug, have received treatment with a drug
             that has not received regulatory approval for any indication

          -  Persons who have previously completed or withdrawn from this study or any other study
             investigating LY2624803 after receiving study drug

          -  Known allergies to LY2624803 or related compounds

          -  Women who are lactating

          -  Shift workers [those who shifted or plan to shift work within 7 days of any phase
             advance polysomnography (PSG) night] or any person who has crossed (or will have
             crossed) more than one time zone by aircraft within 3 days prior to entry

          -  Have an irregular or altered sleep/wake schedule that is likely to prevent from
             keeping a regular sleep/wake schedule during the study

          -  Regular napping (≥ 2 daytime naps/week by history)

          -  Extreme morning type or evening type

          -  Rhinitis, conjunctivitis, urticaria or chronic pain severe enough to interfere with
             sleep

          -  Nocturia that would interfere with sleep assessment

          -  Symptoms consistent with a sleep disorder or history of same

          -  Evidence of significant active neuropsychiatric disease and in particular evidence of
             significant medical or psychiatric illness within the past 12 months that could
             contribute to insomnia

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrine, hematological, neurocardiogenic or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  History or presence of orthostatic signs and symptoms within 2 years

          -  History of seizure or a close relative having a seizure disorder (such as epilepsy).
             History of a single febrile convulsion more than 10 years ago is acceptable. History
             of cranial trauma and loss of consciousness will be discussed prior to including any
             such participant

          -  Abnormal movements observed outside of normal sleep time

          -  Abnormal supine blood pressure and/or pulse rate

          -  Participants with orthostatic hypotension at screening

          -  An abnormality in the 12-lead electrocardiogram (ECG) that increases the risks
             associated with participating in the study

          -  Regular use of known drugs of abuse and/or positive findings on urinary drug screening

          -  Evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies

          -  Evidence of hepatitis C and/or positive hepatitis C antibody

          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Evidence of syphilis infection and/or positive syphilis test

          -  Use or intended use of prescription (except oral contraceptives), over-the-counter or
             herbal medication, specifically antihistamines, anticholinergic medications or any
             medications that affect sleepiness, within 28 days prior to Period 1 dosing and/or
             during the study

          -  Participants who have donated more than 200 milliliters (mL) of blood or component
             blood within one month of screening, or those who have donated more than 400 mL of
             blood within 3 months of screening

          -  History of smoking within the previous 6 months of screening

          -  Participants who have an average weekly alcohol intake that exceeds 21 units per week
             (males) and 14 units per week (females), or participants unwilling to stop alcohol
             consumption for the period

          -  Participants whose daily caffeine intake does not permit maintenance of usual
             sleep/wake schedule

          -  No response to phase advance or a placebo responder

          -  Sleep disorders detected during the PSG screening night

          -  History or presence of breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a double-blind, randomized, placebo-controlled, 4-period cross-over study. The first 3 of which were used for polysomnography (PSG) measurements, and the fourth period was used to determine plasma concentrations of LY2624803 to estimate pharmacokinetic (PK) parameters.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Period 1: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 2: Single dose of one 1.0 milligram (mg) LY2624803 capsule plus placebo solution administered orally.
Period 3: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 4: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Period 1: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 2: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 3: Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 4: Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Period 1: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 2: Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 3: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 4: Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>Period 1: Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 2: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 3: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 4: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>Period 1: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 2: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 3: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 4: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6</title>
          <description>Period 1: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 2: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 3: Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally.
Period 4: Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7</title>
          <description>Period 1: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 2: Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally.
Period 3: Single dose of 1 placebo capsule plus placebo solution administered orally.
Period 4: Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally.
There was at least 7 days washout between each period.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 8</title>
          <description>Period 1: Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally.
Period 2: Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 3: Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally.
Period 4: Single dose of 1.0 mg LY2624803 solution plus 1 placebo capsule administered orally.
There was at least 7 days washout between each period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3">One participant withdrew consent after completed Period 1 and did not enter Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3">One participant withdrew consent after completed Period 2 and did not enter Period 3.</participants>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Single dose of 0.1 mg LY2624803 oral solution plus 1 placebo capsule, one 1.0, 3.0 or 6.0 mg LY2624803 capsule plus placebo solution administered orally in up to 2 of 4 periods or 1 placebo capsule plus placebo solution administered orally in up to 1 of 4 periods.
There was at least 7 days washout between each period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo</title>
        <description>WASO was calculated as total time in awake epochs between sleep onset time (first stage 2 epoch) and the end of the primary recording period (8 hours after lights -off). Data presented are Geometric Least Squares (LS) means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
        <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY2624803</title>
            <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg LY2624803</title>
            <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg LY2624803</title>
            <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>6.0 mg LY2624803</title>
            <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of 1 placebo capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo</title>
          <description>WASO was calculated as total time in awake epochs between sleep onset time (first stage 2 epoch) and the end of the primary recording period (8 hours after lights -off). Data presented are Geometric Least Squares (LS) means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
          <units>minutes (min)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.88" lower_limit="33.32" upper_limit="104.05"/>
                    <measurement group_id="O2" value="40.70" lower_limit="25.67" upper_limit="64.54"/>
                    <measurement group_id="O3" value="32.27" lower_limit="20.27" upper_limit="51.37"/>
                    <measurement group_id="O4" value="18.42" lower_limit="10.44" upper_limit="32.51"/>
                    <measurement group_id="O5" value="61.10" lower_limit="38.60" upper_limit="96.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.908</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of Geometric LS mean</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS mean is WASO of 0.1 mg LY2624803 / Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of Geometric LS mean</param_type>
            <param_value>0.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS mean is WASO of 1.0 mg LY2624803 / Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of Geometric LS mean</param_type>
            <param_value>0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS mean is WASO of 3.0 mg LY2624803 / Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of Geometric LS mean</param_type>
            <param_value>0.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Ratio of Geometric LS mean is WASO of 6.0 mg LY2624803 / Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Latency to Persistent Sleep (LPS)</title>
        <description>LPS is defined as the latency from the lights-off time to the first stage 2 sleep followed by at least 10 consecutive minutes of sleep epochs. Data presented are Geometric LS means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
        <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY2624803</title>
            <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg LY2624803</title>
            <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg LY2624803</title>
            <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>6.0 mg LY2624803</title>
            <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of 1 placebo capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Latency to Persistent Sleep (LPS)</title>
          <description>LPS is defined as the latency from the lights-off time to the first stage 2 sleep followed by at least 10 consecutive minutes of sleep epochs. Data presented are Geometric LS means. Geometric LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
          <units>min</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.30" lower_limit="7.41" upper_limit="27.59"/>
                    <measurement group_id="O2" value="8.39" lower_limit="5.41" upper_limit="13.02"/>
                    <measurement group_id="O3" value="7.84" lower_limit="5.01" upper_limit="12.28"/>
                    <measurement group_id="O4" value="7.27" lower_limit="3.78" upper_limit="13.99"/>
                    <measurement group_id="O5" value="10.40" lower_limit="6.72" upper_limit="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time (TST)</title>
        <description>TST is defined as the total time in sleep epochs from sleep onset time to the end of the primary recording period (8 hours after lights -off). LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
        <time_frame>8 hours in Periods 1, 2 and 3</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY2624803</title>
            <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg LY2624803</title>
            <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg LY2624803</title>
            <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O4">
            <title>6.0 mg LY2624803</title>
            <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of 1 placebo capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time (TST)</title>
          <description>TST is defined as the total time in sleep epochs from sleep onset time to the end of the primary recording period (8 hours after lights -off). LS mean was calculated using mixed models analysis. The model included factors for treatment, treatment sequence, period and participants.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had PSG measurements in Periods 1, 2 and 3.</population>
          <units>min</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.37" lower_limit="333.21" upper_limit="415.53"/>
                    <measurement group_id="O2" value="404.35" lower_limit="373.53" upper_limit="435.17"/>
                    <measurement group_id="O3" value="420.65" lower_limit="389.43" upper_limit="451.88"/>
                    <measurement group_id="O4" value="452.09" lower_limit="411.06" upper_limit="493.12"/>
                    <measurement group_id="O5" value="373.78" lower_limit="343.12" upper_limit="404.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Maximum Plasma Concentration (Cmax) of LY2624803 After Single Oral Dose in Period 4</title>
        <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4</time_frame>
        <population>All randomized participants who received a single oral dose of LY2624803 in Period 4 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY2624803</title>
            <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Period 4</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg LY2624803</title>
            <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg LY2624803</title>
            <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
          <group group_id="O4">
            <title>6.0 mg LY2624803</title>
            <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Plasma Concentration (Cmax) of LY2624803 After Single Oral Dose in Period 4</title>
          <population>All randomized participants who received a single oral dose of LY2624803 in Period 4 and had evaluable PK data.</population>
          <units>nanograms/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" spread="10"/>
                    <measurement group_id="O2" value="43.8" spread="10"/>
                    <measurement group_id="O3" value="146" spread="13"/>
                    <measurement group_id="O4" value="251" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2624803 After Single Oral Dose in Period 4</title>
        <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 10, 12, 18, and 42 hours post-dose in Period 4</time_frame>
        <population>All randomized participants who received a single oral dose of LY2624803 in Period 4 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg LY2624803</title>
            <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Period 4</description>
          </group>
          <group group_id="O2">
            <title>1.0 mg LY2624803</title>
            <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
          <group group_id="O3">
            <title>3.0 mg LY2624803</title>
            <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
          <group group_id="O4">
            <title>6.0 mg LY2624803</title>
            <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2624803 After Single Oral Dose in Period 4</title>
          <population>All randomized participants who received a single oral dose of LY2624803 in Period 4 and had evaluable PK data.</population>
          <units>nanograms•hour/milliliter (ng•hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="39"/>
                    <measurement group_id="O2" value="714" spread="20"/>
                    <measurement group_id="O3" value="2240" spread="34"/>
                    <measurement group_id="O4" value="4220" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.1 mg LY2624803 - Periods 1-3</title>
          <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Periods 1, 2 and 3.</description>
        </group>
        <group group_id="E2">
          <title>1.0 mg LY2624803 - Periods 1-3</title>
          <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
        </group>
        <group group_id="E3">
          <title>3.0 mg LY2624803 - Periods 1-3</title>
          <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
        </group>
        <group group_id="E4">
          <title>6.0 mg LY2624803 - Periods 1-3</title>
          <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
        </group>
        <group group_id="E5">
          <title>Placebo - Periods 1-3</title>
          <description>Single dose of 1 placebo capsule plus placebo solution administered orally in Periods 1, 2 and 3.</description>
        </group>
        <group group_id="E6">
          <title>0.1 mg LY2624803 - Period 4</title>
          <description>Single dose of 0.1 mg LY2624803 solution plus 1 placebo capsule administered orally in Period 4.</description>
        </group>
        <group group_id="E7">
          <title>1.0 mg LY2624803 - Period 4</title>
          <description>Single dose of one 1.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4.</description>
        </group>
        <group group_id="E8">
          <title>3.0 mg LY2624803 - Period 4</title>
          <description>Single dose of one 3.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4.</description>
        </group>
        <group group_id="E9">
          <title>6 mg LY2624803 - Period 4</title>
          <description>Single dose of one 6.0 mg LY2624803 capsule plus placebo solution administered orally in Period 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

